In a significant development in the world of biosimilars, the U.S. Food and Drug Administration (FDA) has bestowed upon Pfizer Inc.’s ABRILADA (adalimumab-afzb) the status of an interchangeable biosimilar to HUMIRA (adalimumab). This news was announced by Pfizer themselves on October 5, 2023. It marks an advancement in the utilization of biosimilars, and more specifically, of adalimumab biosimilars.
The FDA’s approval complements the initial acceptance of ABRILADA by the federal agency in November 2019. This interchangeable designation elevates ABRILADA’s standing within the pharmaceutical industry, and potentially paves the way for increased implementation of biosimilars in healthcare practices.
Adalimumab, sold under the trade name HUMIRA, is an extremely significant medication in the treatment of various autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Biosimilars like ABRILADA offer the promise of similar efficacy at potentially lower costs. The granting of an interchangeable status signifies FDA’s confidence in ABRILADA offering a level of therapeutic consistency on par with HUMIRA.
Interest in biosimilars has been growing steadily worldwide due to their potential to provide cost-effective alternatives to high-priced biologic drugs. ABRILADA’s interchangeable designation by the FDA exemplifies the growing confidence and acceptance of biosimilars in the U.S. healthcare system.
For further details on this recent development in adalimumab biosimilar applications, visit this JD Supra report.